Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EXAS 
EXACT Sciences Corporation (EXAS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: EXAS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
26 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $70.25
1 Year Target Price $70.25
| 17 | Strong Buy |
| 6 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -9.27% | Avg. Invested days 39 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 12.25B USD | Price to earnings Ratio - | 1Y Target Price 70.25 |
Price to earnings Ratio - | 1Y Target Price 70.25 | ||
Volume (30-day avg) 26 | Beta 1.24 | 52 Weeks Range 38.81 - 72.83 | Updated Date 11/2/2025 |
52 Weeks Range 38.81 - 72.83 | Updated Date 11/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-03 | When After Market | Estimate -0.0076 | Actual - |
Profitability
Profit Margin -34.19% | Operating Margin (TTM) 0.34% |
Management Effectiveness
Return on Assets (TTM) -1.39% | Return on Equity (TTM) -35.51% |
Valuation
Trailing PE - | Forward PE 90.91 | Enterprise Value 12300862790 | Price to Sales(TTM) 4.17 |
Enterprise Value 12300862790 | Price to Sales(TTM) 4.17 | ||
Enterprise Value to Revenue 4.18 | Enterprise Value to EBITDA 215.11 | Shares Outstanding 189319110 | Shares Floating 187477035 |
Shares Outstanding 189319110 | Shares Floating 187477035 | ||
Percent Insiders 0.91 | Percent Institutions 96.74 |
Upturn AI SWOT
EXACT Sciences Corporation
Company Overview
History and Background
EXACT Sciences Corporation was founded in 1995. It initially focused on developing stool-based DNA technology for colorectal cancer screening. The company's evolution has been marked by the development and commercialization of Cologuard and strategic acquisitions to expand its cancer diagnostics portfolio.
Core Business Areas
- Colorectal Cancer Screening: Focuses on the development and commercialization of Cologuard, a non-invasive stool DNA screening test for colorectal cancer.
- Precision Oncology: Develops and commercializes genomic tests to help guide cancer treatment decisions for patients with advanced cancer.
- Multi-Cancer Early Detection: Focuses on developing blood-based tests to detect multiple types of cancer at early stages.
Leadership and Structure
The leadership team is headed by Kevin Conroy (Chairman & CEO). The company has a standard corporate structure with departments spanning R&D, commercial operations, finance, and legal.
Top Products and Market Share
Key Offerings
- Cologuard: Cologuard is a non-invasive stool DNA screening test for colorectal cancer. It has a significant market share in the at-home colorectal cancer screening market. Competitors include traditional colonoscopies, fecal immunochemical tests (FIT), and other stool DNA tests. Cologuard test volume was 2.99 million in 2023, up 21% year over year. Market share is significant, but difficult to quantify exactly due to the fragmented nature of screening methods.
- OncoType DX: OncoType DX is a portfolio of genomic tests that analyzes the activity of specific genes in a tumor sample to predict how likely a cancer is to spread and how likely it is to respond to certain treatments. Competitors include Foundation Medicine (FMI), Guardant Health (GH), and Myriad Genetics (MYGN).
Market Dynamics
Industry Overview
The cancer diagnostics industry is experiencing significant growth, driven by advancements in genomics and personalized medicine, an aging population, and increasing awareness of early cancer detection benefits.
Positioning
EXACT Sciences is a leading player in the non-invasive cancer screening and precision oncology markets. Its competitive advantages include a strong brand reputation, established relationships with healthcare providers, and a robust R&D pipeline.
Total Addressable Market (TAM)
The total addressable market for cancer diagnostics is estimated to be in the tens of billions of dollars. EXACT Sciences is well-positioned to capture a significant portion of this market through its diverse product portfolio and continued innovation.
Upturn SWOT Analysis
Strengths
- Strong brand recognition with Cologuard
- Established relationships with healthcare providers
- Robust R&D pipeline
- Diverse product portfolio
- Strong sales and marketing capabilities
Weaknesses
- High operating expenses
- Dependence on Cologuard for a significant portion of revenue
- Competition from established players in the diagnostics market
- Negative net income
Opportunities
- Expansion into new cancer screening markets
- Development of new genomic tests
- Partnerships with pharmaceutical companies
- Increasing awareness of early cancer detection benefits
- Growing adoption of personalized medicine
Threats
- Changes in healthcare regulations
- Reimbursement pressures from insurance companies
- Competition from new entrants in the diagnostics market
- Clinical trial failures
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- GHDX
- FMI
- ILMN
- HOLX
- DGX
Competitive Landscape
EXACT Sciences competes with a range of companies in the cancer diagnostics market, including established players and new entrants. Its competitive advantages include a strong brand reputation, a diverse product portfolio, and a robust R&D pipeline. However, the company faces challenges from reimbursement pressures, regulatory changes, and competition from other diagnostic providers.
Major Acquisitions
Genomic Health
- Year: 2019
- Acquisition Price (USD millions): 2800
- Strategic Rationale: Expanded EXACT Sciences' portfolio into precision oncology, providing tests for treatment decisions in breast, prostate, and colon cancer.
PreventionGenetics
- Year: 2021
- Acquisition Price (USD millions): 190
- Strategic Rationale: Expanded EXACT Sciences' portfolio into hereditary cancer testing.
Growth Trajectory and Initiatives
Historical Growth: EXACT Sciences has experienced rapid revenue growth over the past several years, driven by the increasing adoption of Cologuard. The company has also made strategic acquisitions to expand its product portfolio and market reach.
Future Projections: Analysts project continued revenue growth for EXACT Sciences, driven by increasing adoption of its existing products and the launch of new genomic tests. Profitability is expected to improve over time as the company achieves greater scale and operational efficiency.
Recent Initiatives: Recent initiatives include expansion of Cologuard sales force, development of new multi-cancer early detection tests, and strategic acquisitions to expand the company's precision oncology portfolio.
Summary
EXACT Sciences is a leading company in cancer diagnostics with its flagship product, Cologuard, driving significant revenue growth. The company's strategic acquisitions have broadened its offerings in precision oncology. However, EXACT Sciences is still operating at a net loss, reliant on Cologuard, and exposed to competitive pressures and evolving regulations. Continued innovation in multi-cancer detection and expansion into new markets will be critical for sustained growth and profitability.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q)
- Investor Presentations
- Analyst Reports
- Press Releases
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data and analyst estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About EXACT Sciences Corporation
Exchange NASDAQ | Headquaters Madison, WI, United States | ||
IPO Launch date 2001-02-01 | Chairman of the Board & CEO Mr. Kevin T. Conroy J.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 6900 | Website https://www.exactsciences.com |
Full time employees 6900 | Website https://www.exactsciences.com | ||
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.